Cargando…
The treatment of advanced renal cell cancer with high-dose oral thalidomide
Thalidomide is reported to suppress levels of several cytokines, angiogenic and growth factors including TNF-α, basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6). The resulting anti-angiogenic, immunomodulatory and growth suppressive effects fo...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375104/ https://www.ncbi.nlm.nih.gov/pubmed/11592764 http://dx.doi.org/10.1054/bjoc.2001.2025 |
_version_ | 1782154578221858816 |
---|---|
author | Stebbing, J Benson, C Eisen, T Pyle, L Smalley, K Bridle, H Mak, I Sapunar, F Ahern, R Gore, M E |
author_facet | Stebbing, J Benson, C Eisen, T Pyle, L Smalley, K Bridle, H Mak, I Sapunar, F Ahern, R Gore, M E |
author_sort | Stebbing, J |
collection | PubMed |
description | Thalidomide is reported to suppress levels of several cytokines, angiogenic and growth factors including TNF-α, basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6). The resulting anti-angiogenic, immunomodulatory and growth suppressive effects form the rationale for investigating thalidomide in the treatment of malignancies. We have evaluated the use of high-dose oral thalidomide (600 mg daily) in patients with renal carcinoma. 25 patients (all men; median age, 51 years; range 34–76 years) with advanced measurable renal carcinoma, who had either progressed on or were not suitable for immunotherapy, received thalidomide in an escalating schedule up to a maximum dose of 600 mg daily. Treatment continued until disease progression or unacceptable toxicity were encountered. 22 patients were assessable for response. 2 patients showed partial responses (9%; 95% CI: 1–29), 7 (32%; 95% CI: 14–55) had stable disease for more than 6 months and a further 5 (23%; 95% CI: 8–45) had stable disease for between 3 and 6 months. We also measured levels of TNF-α, bFGF, VEGF, IL-6 and IL-12 before and during treatment. In patients with SD ≥ 3 months or an objective response, a statistically significant decrease in serum TNF-α levels was demonstrated (P = 0.05). The commonest toxicities were lethargy (≥ grade II, 10 patients), constipation (≥ grade II, 11 patients) and neuropathy (≥ grade II, 5 patients). Toxicities were of sufficient clinical significance for use of a lower and well tolerated dose of 400 mg in currently accruing studies. © 2001 Cancer Research Campaignhttp://www.bjcancer.com |
format | Text |
id | pubmed-2375104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2001 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23751042009-09-10 The treatment of advanced renal cell cancer with high-dose oral thalidomide Stebbing, J Benson, C Eisen, T Pyle, L Smalley, K Bridle, H Mak, I Sapunar, F Ahern, R Gore, M E Br J Cancer Regular Article Thalidomide is reported to suppress levels of several cytokines, angiogenic and growth factors including TNF-α, basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6). The resulting anti-angiogenic, immunomodulatory and growth suppressive effects form the rationale for investigating thalidomide in the treatment of malignancies. We have evaluated the use of high-dose oral thalidomide (600 mg daily) in patients with renal carcinoma. 25 patients (all men; median age, 51 years; range 34–76 years) with advanced measurable renal carcinoma, who had either progressed on or were not suitable for immunotherapy, received thalidomide in an escalating schedule up to a maximum dose of 600 mg daily. Treatment continued until disease progression or unacceptable toxicity were encountered. 22 patients were assessable for response. 2 patients showed partial responses (9%; 95% CI: 1–29), 7 (32%; 95% CI: 14–55) had stable disease for more than 6 months and a further 5 (23%; 95% CI: 8–45) had stable disease for between 3 and 6 months. We also measured levels of TNF-α, bFGF, VEGF, IL-6 and IL-12 before and during treatment. In patients with SD ≥ 3 months or an objective response, a statistically significant decrease in serum TNF-α levels was demonstrated (P = 0.05). The commonest toxicities were lethargy (≥ grade II, 10 patients), constipation (≥ grade II, 11 patients) and neuropathy (≥ grade II, 5 patients). Toxicities were of sufficient clinical significance for use of a lower and well tolerated dose of 400 mg in currently accruing studies. © 2001 Cancer Research Campaignhttp://www.bjcancer.com Nature Publishing Group 2001-09 /pmc/articles/PMC2375104/ /pubmed/11592764 http://dx.doi.org/10.1054/bjoc.2001.2025 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Stebbing, J Benson, C Eisen, T Pyle, L Smalley, K Bridle, H Mak, I Sapunar, F Ahern, R Gore, M E The treatment of advanced renal cell cancer with high-dose oral thalidomide |
title | The treatment of advanced renal cell cancer with high-dose oral thalidomide |
title_full | The treatment of advanced renal cell cancer with high-dose oral thalidomide |
title_fullStr | The treatment of advanced renal cell cancer with high-dose oral thalidomide |
title_full_unstemmed | The treatment of advanced renal cell cancer with high-dose oral thalidomide |
title_short | The treatment of advanced renal cell cancer with high-dose oral thalidomide |
title_sort | treatment of advanced renal cell cancer with high-dose oral thalidomide |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375104/ https://www.ncbi.nlm.nih.gov/pubmed/11592764 http://dx.doi.org/10.1054/bjoc.2001.2025 |
work_keys_str_mv | AT stebbingj thetreatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT bensonc thetreatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT eisent thetreatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT pylel thetreatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT smalleyk thetreatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT bridleh thetreatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT maki thetreatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT sapunarf thetreatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT ahernr thetreatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT goreme thetreatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT stebbingj treatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT bensonc treatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT eisent treatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT pylel treatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT smalleyk treatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT bridleh treatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT maki treatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT sapunarf treatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT ahernr treatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide AT goreme treatmentofadvancedrenalcellcancerwithhighdoseoralthalidomide |